Published Date: 13 Mar 2023
Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.
Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.
A study reveals EEG and MRI biomarkers in MOGAD patients with epilepsy, highlighting potential early indicators for refractory epilepsy and improved treatment outcomes.
Despite the availability of antiseizure medications approved for Dravet syndrome, a recent survey presented at AES 2025 showed that these therapies remain underutilized in patients.
Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis
1.
According to research, hospitals can save money and help cancer patients by implementing a basic intervention.
2.
Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds
3.
A Lot Can Be Said About You by Including Yourself in Photos.
4.
Watch for Psoriasis After Cancer Immunotherapy, Study Says
5.
Coupling dye and fiducial marking can improve precision in pulmonary nodule surgical resection
1.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
2.
Liquid Biopsies Unveiling the Future of Precision Cancer Management by 2025
3.
The Latest Causes and Symptoms of Bowen's Disease: All You Need to Know
4.
Rasburicase-Linked Methemoglobinemia in HCC: Risks, Mechanisms, and Management
5.
Understanding Cold Agglutinin Disease: Symptoms, Diagnosis, and Treatment Options
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation